RVTY

REVVITY INC

Apr 05 • 04:00PM ET

93.26

+2.86 (+3.16%)

Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company's Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorder ... read more

Full Time Employees 11,000

Phone 781 663 6900

Website https://www.perkinelmer.com

CEO Dr. Prahlad R. Singh Ph.D.

IPO Date 1965-07-06

Sector Healthcare

Industry Medical - Diagnostics & Research

Address 940 Winter Street, Waltham, MA 02451

Balance Sheet

Total Cash $1,137,620,000

Total Debt $3,325,365,000

Current Ratio 3.58

Quick Ratio 2.71

Profitability

Gross Margin 56.25%

Net Margin 10.35%

ROE 3.75%

ROA 2.32%

ROIC 3.02%

Balance Sheet

Total Cash $1,137,620,000

Total Debt $3,325,365,000

Current Ratio 3.58

Quick Ratio 2.71

Profitability

Gross Margin 56.25%

Net Margin 10.35%

ROE 3.75%

ROA 2.32%

ROIC 3.02%

Name	REVVITY INC	Sector	Healthcare	Currency	USD	Relative Volume	2.16	Market Cap	11398
Current Ratio	3.6	Dividend / Share	0.28	EPS	2.2	Revenue	2755026000	P/S	4.1
P/E	42.2	Beta	0.79	Income	270385000	Volume	2108290	Average Volume	976692
Distance to 200DMA	-18.32%	200 DMA	116.11	50 DMA	113.39	ROA	2.1	ROE	3.5
Distance to 50DMA	-16.36%	Return 1Y	-7.1%	Return YTD	-14.98%	Forward PE		Qtly Growth YOY
Debt/Eq	0.62	P/B	1.5	Dividend Yield	0.3%	Net Margin	9.81%	Payout Ratio	12.7

Performance

52 Week Range 12.7%

Distance to 200DMA 0.15%

Day Change Percent $0.14

Performance Week $0.07

Performance Month $0.07

Performance Quarter 2024-10-18

Performance YTD $0.07

Performance Year $0.07

Performance Range

Day

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Balance Sheet

Total Cash $1,229,778,000

Total Debt $3,315,143,000

Current Ratio 3.56%

Quick Ratio 2.66%

Profitability

Valuation

Price to Earnings 39.09

Price to Book 1.47

Price to Sales 4.04

Price to Free Cash Flow 21.38

Dividends

Payout Ratio 11.74%

Dividend Yield 0.30%

Dividend Amount $0.14

Last Dividend Pay Date 2024-10-18

Last Dividend Paid $0.07

Performance

52 Week Range 12.7%

Distance to 200DMA 0.15%

Day Change Percent $0.14

Performance Week $0.07

Performance Month $0.07

Performance Quarter 2024-10-18

Performance YTD $0.07

Performance Year $0.07

Company Profile

Full Time Employees 11,000

Phone 781 663 6900

Website https://www.perkinelmer.com

CEO Dr. Prahlad R. Singh Ph.D.

IPO Date 1965-07-06

Sector Healthcare

Address 940 Winter Street, Waltham, MA 02451

Histogram - Daily

Balance Sheet

Total Cash $1,229,778,000

Total Debt $3,315,143,000

Current Ratio 3.56%

Quick Ratio 2.66%

Profitability

Gross Margin 0.5540%

Net Margin 0.0930%

ROE 0.03%

ROA 0.02%

Company Profile

Full Time Employees 11,000

Phone 781 663 6900

Website https://www.perkinelmer.com

CEO Dr. Prahlad R. Singh Ph.D.

IPO Date 1965-07-06

Sector Healthcare

Address 940 Winter Street, Waltham, MA 02451

Monthly Win Rate

Balance Sheet (Multi-Column Example)

	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Cash & Short Term Investments	53,775.0	65,171.0	61,801.0	67,150.0	73,100.0	61,555.0	62,482.0	55,872.0
Receivables	59,306.0	66,243.0	43,172.0	41,150.0	50,102.0	60,985.0	39,186.0	35,899.0
Inventory	6,911.0	7,286.0	6,165.0	6,232.0	6,511.0	6,331.0	7,351.0	7,482.0

Latest News

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy

Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the

2025-05-09 10:35:37 - seekingalpha.com

RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up

Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.

2025-04-28 14:20:36 - zacks.com

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chie

2025-04-28 11:49:08 - seekingalpha.com

Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t

2025-04-28 10:31:04 - zacks.com

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Ma

Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.

2025-04-28 09:14:46 - benzinga.com

Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates

Revvity (RVTY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.98 per share a year ago.

2025-04-28 08:15:35 - zacks.com

Revvity beats quarterly estimates on steady demand for medical equipment

Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for d

2025-04-28 07:32:39 - reuters.com

Revvity Announces Financial Results for the First Quarter of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as comp

2025-04-28 06:00:00 - businesswire.com

Why Revvity (RVTY) Could Beat Earnings Estimates Again

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2025-04-25 13:15:43 - zacks.com

Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?

RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.

2025-04-25 09:00:44 - zacks.com

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2

2025-04-24 16:05:00 - businesswire.com

Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2025-04-21 11:05:53 - zacks.com

Revvity to Hold Earnings Call on Monday, April 28, 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company w

2025-04-03 08:00:00 - businesswire.com

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's strong product portfolio raises optimism about the stock.

2025-04-02 08:51:06 - zacks.com

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discov

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved

2025-04-02 08:00:00 - businesswire.com

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.

2025-04-02 08:00:00 - businesswire.com